Global Tinea Pedis Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Tinea pedis is a fungal infection of the feet caused by dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, which can spread to the toes and hands. These fungi prefer warm, moist environments and are spread by coming into contact with an infected person. In areas with tropical and subtropical climates, tinea pedis is more prevalent. In the interdigital regions of the hands and feet, tinea pedis can cause maceration, evident fissuring, and scaling. When tinea pedis is just weakly infected, it can be treated with topical antifungals, but severe infections need oral antifungal medications. The rising prevalence of fungal infections caused by worms and bacteria, as well as growing geriatric population is contributing towards the growth of the Global Tinea Pedis Market.

As per World Health Organization, the incidences of fungal infections have significantly increased over the years due to global warming and the increase in international travel and trade. For instance – as per Global Action for Fungal Infection (GAFFI) organization estimates- as of 2022, Globally over 300 million individuals are afflicted with a serious fungal infection and more than 25 million are at high risk of dying. Furthermore, the increasing number of geriatric individuals is another factor driving the market growth. According to the World Bank Group, the world’s old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Also, rise in the number of immunocompromised patients and growing healthcare industry in developing economies would offer lucrative growth opportunities for the market over the projected period. However, high cost of Tinea Pedis Treatment and stringent drug approval process hinder the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Tinea Pedis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the increasing number of new product development from leading market players in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing incidences of fungal infections in the region.

Major market players included in this report are:
Zimmer Biomet
Smith & Nephew
Djo (Encore)
Zirkonzahn
Waldemar Link
Dragonbio
Stryker
Aesculap (B. Braun)
United Orthopedic Corporation
GlaxoSmithKline PLC

Recent Developments in the Market:
? In March 2022, Blueberry Therapeutics Limited, a leading company offering topical medicines to treat dermatological conditions, announced the commencement of research and development activities for new formulations for onychomycosis (fungal nail infection), tinea pedis (athlete’s foot) and atopic dermatitis (eczema).


Global Tinea Pedis Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Disease Type, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease Type
Interdigital Tinea Pedis
Plantar Tinea Pedis
Vesicular Tinea Pedis

By Route of Administration
Oral
Topical

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World